Composition using 4′,6,7-trimethoxyisoflavone and catechol for managing pulmonary fibrosis
US12263154B2 · kind B2 · utility
0Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 6, 2021 |
| Grant date | Apr 1, 2025 |
| Priority date | — |
| Expiry date | Jul 26, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P11/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Proposed is a composition for managing pulmonary fibrosis. The composition uses 4′,6,7-trimethoxyisoflavone and catechol that does not cytotoxicity and inhibits a TGF-β1 signal transfer pathway, thereby exhibiting EMT inhibitory activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.